论文部分内容阅读
一项名为SPARC(Satraplatin and Prednisone Against Refrac-tory Cancer))的Ⅲ期临床实验研究得出的数据表明,GPC Bio-tech公司研发的化疗药satraplatin可使前列腺癌进展的危险性降低40%。这一结果将为satraplatin申请新药证书提供有力的支持。Satraplatin是GPC Biotech公司于
A Phase III clinical trial called SPARC (Satraplatin and Prednisone Against Refractory Cancer) data showed that satraplatin, a chemotherapeutic drug developed by GPC Bio-tech, can reduce the risk of prostate cancer by 40%. This result will provide strong support for the new drug certificate for satraplatin. Satraplatin is a GPC Biotech company